Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.
The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of "hold" with a mean price target of $50.35.
The biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.